DCMIC
PHAT icon

Decheng Capital Management III (Cayman)’s Phathom Pharmaceuticals PHAT Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$8.81M Hold
850,000
– – 2.94% 13
2023
Q2 		$12.2M Buy
+850,000
New +$9.8M 3.82% 9

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s PHAT Position: Q3 2023 in Review

Decheng Capital Management III (Cayman) held its Phathom Pharmaceuticals (PHAT) position steady in Q3 2023 at 850,000 shares worth $8.81M. The position accounts for 2.94% of the portfolio, ranked #13.

Decheng Capital Management III (Cayman) first reported a position in PHAT in Q2 2023 and has held it in 2 quarters since. The position peaked at $12.2M in Q2 2023. 110 funds tracked by Wall St. Rank hold PHAT as of Q3 2023.

  • Decheng Capital Management III (Cayman) held 850,000 shares of Phathom Pharmaceuticals worth $8.81M as of Q3 2023.
  • Decheng Capital Management III (Cayman) left its Phathom Pharmaceuticals share count unchanged in Q3 2023.
  • Phathom Pharmaceuticals made up 2.94% of Decheng Capital Management III (Cayman)'s portfolio in Q3 2023, its #13 holding.
  • Decheng Capital Management III (Cayman) first reported a position in Phathom Pharmaceuticals in Q2 2023 and has held it in 2 quarters since.
  • Decheng Capital Management III (Cayman)'s Phathom Pharmaceuticals position peaked at $12.2M in Q2 2023.
  • 110 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.